Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma

Abstract

Abstract. T helper 17 (Th17), T cytotoxic 17 (Tc17) and regulatory T (Treg) cells serve important roles in a number of inflammatory and autoimmune diseases. The aim of the present study was to examine the distribution of Th17, Tc17 and Treg cells in patients with differentiated thyroid cancer (DTC) prior to as well as 7, 30 and 90 days following radioactive iodine-131 ( 131 I) therapy, and to elucidate the probable effects of 131 I therapy on Th17/Tc17 and Treg/Th17 cells in patients with DTC. A total of 40 patients with DTC (26 female; 14 male) between the ages of 24 and 72 years, as well as 13 age-and sex-matched healthy subjects were included in this study. The number of Th17, Tc17 and Treg cells in the peripheral blood of patients with DTC and of healthy Controls were assessed by flow cytometry. Th17 and Tc17 cells were counted as percentages of the number of CD3 + T cells; Treg cells were counted as a percentage of the number of CD4 +

Prophylactic and therapeutic immunomodulatory effects of omega-3 fatty acids in patients with differentiated thyroid cancer scheduled for radioiodine ablation

“…Decreased IL-17F and IL-21 after RAI ablation may prevent tumor invasion by reducing inflammation. Our results are consistent with Zhang et al, who reported an elevated frequency of Th17 cells in peripheral blood and their related serum cytokines in patients with DTC compared to healthy controls, a significant decline in these markers 2 week after 131 I therapy, and a return to normal levels after 3 months [36]. It is worth noting that, considering the complex interactions among cytokines within an extensive network, increased IL-10 alone or decreased IL-17 and IL-21 without affecting overall cytokine balance may not result in any specific biological effect [37] There is evidence in support of the beneficial effects of omega-3 on recovery in patients who undergo chemotherapy, radiotherapy, or both [38].…”

“…Cytokines play a crucial role in the regulation of immune responses, and cytokine imbalances have been related with different diseases [8]. Changes in cytokines have been reported in patients with different types of cancers in previous studies [9,10], but the data are limited regarding cytokine alterations in thyroid cancer, and particularly after RAI ablation in patients with DTC [11][12][13].…”

Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice

“…Serum level of IL-17 increases significantly in patients with thyroid tumors compared with healthy controls (52,53). And its serum expression level of thyroid cancer is higher than that of thyroid adenoma, suggesting that it could be used as a potential biomarker to distinguish thyroid cancer from adenoma (54).…”

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition

“…IL17RA polymorphisms negatively correlated with the development of PTC [65]. The serum levels of IL-17 and the percentage of Th17, Tc17, and T regulatory cells (Tregs) were increased in patients with DTCs compared to healthy controls [66]. IL-17 and IL-23 expression in DTCs and MTCs were increased compared to thyroid adenoma, and IL-17 expression was associated with recurrence and mortality [67].…”